Page 38 - Read Online

Min et al. Metab Target Organ Damage 2023;3:6 https://dx.doi.org/10.20517/mtod.2023.09 Page 9 of 10

reports personal fees and travel grants from AstraZeneca, Boehringer Ingelheim, Napp and Abbott Diabetes
Care.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of
scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 2018;17:83. DOI PubMed PMC
2. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients
with type 2 diabetes. N Engl J Med 2003;348:383-93. DOI PubMed
3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the american
diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care 2022;45:2753-86. DOI
PubMed PMC
4. FDA. Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry.
Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-2-diabetes-mellitus-evaluating-
safety-new-drugs-improving-glycemic-control-guidance-industry [Last accessed on 13 May 2023].
5. Cosentino F, Grant PJ, Aboyans V, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323. DOI PubMed
6. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary
syndrome. N Engl J Med 2015;373:2247-57. DOI
7. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22. DOI PubMed PMC
8. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2
diabetes. N Engl J Med 2016;375:1834-44. DOI PubMed
9. Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-Weekly exenatide on cardiovascular outcomes in
type 2 diabetes. N Engl J Med 2017;377:1228-39. DOI PubMed PMC
10. Hernandez AF, Green JB, Janmohamed S, et al; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular
outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-
controlled trial. Lancet 2018;392:1519-29. DOI
11. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes
(REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. DOI PubMed
12. Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients
with type 2 diabetes. N Engl J Med 2019;381:841-51. DOI PubMed
13. Gerstein HC, Sattar N, Rosenstock J, et al; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide
in type 2 diabetes. N Engl J Med 2021;385:896-907. DOI
14. Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular
outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 2022;28:89-95. DOI PubMed
15. Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther
2020;11:835-44. DOI PubMed PMC
16. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with
type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-85.
DOI
17. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-
glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 2022;145:565-
74. DOI
18. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events
in type 2 diabetes. N Engl J Med 2017;377:644-57. DOI PubMed
19. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2
diabetes. N Engl J Med 2019;380:347-57. DOI PubMed